KAPA
Kairos Pharma, Ltd. AMEX Listed Sep 16, 2024$0.55
Mkt Cap $11.9M
52w Low $0.40
9.0% of range
52w High $2.11
50d MA $0.60
200d MA $0.89
P/E (TTM)
-1.9x
EV/EBITDA
-1.6x
P/B
1.6x
Debt/Equity
0.0x
ROE
-85.9%
P/FCF
-3.8x
RSI (14)
—
ATR (14)
—
Beta
1.98
50d MA
$0.60
200d MA
$0.89
Avg Volume
506.9K
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.
CIK (SEC)
Phone
310-948-2356
2355 Westwood Blvd. · Los Angeles, CA 90064 · US
Data updated apr 25, 2026 5:11pm
· Source: massive.com